Gennova Biopharmaceuticals on Tuesday received approval from the Drugs Controller General of India (DCGI) to start Phase II/III trials for its Covid-19 vaccine. Gennova has developed the HGCO19 Covid-19 vaccine, which is the country’s first mRNA-based vaccine. The company has committed to making 60 million doses by the year-end.

Leave a Reply

Your email address will not be published. Required fields are marked *